ZA200710769B - Dosage regimen for prasugrel - Google Patents
Dosage regimen for prasugrelInfo
- Publication number
- ZA200710769B ZA200710769B ZA200710769A ZA200710769A ZA200710769B ZA 200710769 B ZA200710769 B ZA 200710769B ZA 200710769 A ZA200710769 A ZA 200710769A ZA 200710769 A ZA200710769 A ZA 200710769A ZA 200710769 B ZA200710769 B ZA 200710769B
- Authority
- ZA
- South Africa
- Prior art keywords
- prasugrel
- dosage regimen
- regimen
- dosage
- Prior art date
Links
- 239000005465 B01AC22 - Prasugrel Substances 0.000 title 1
- DTGLZDAWLRGWQN-UHFFFAOYSA-N prasugrel Chemical compound C1CC=2SC(OC(=O)C)=CC=2CN1C(C=1C(=CC=CC=1)F)C(=O)C1CC1 DTGLZDAWLRGWQN-UHFFFAOYSA-N 0.000 title 1
- 229960004197 prasugrel Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4743—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69174005P | 2005-06-17 | 2005-06-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200710769B true ZA200710769B (en) | 2009-09-30 |
Family
ID=37571073
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200710769A ZA200710769B (en) | 2005-06-17 | 2007-12-11 | Dosage regimen for prasugrel |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20090156632A1 (enExample) |
| EP (1) | EP1893205A4 (enExample) |
| JP (1) | JP2008543853A (enExample) |
| KR (1) | KR20080016647A (enExample) |
| CN (1) | CN101198329A (enExample) |
| AU (1) | AU2006259538A1 (enExample) |
| BR (1) | BRPI0612624A2 (enExample) |
| CA (1) | CA2612315A1 (enExample) |
| EA (1) | EA200800075A1 (enExample) |
| EC (1) | ECSP078014A (enExample) |
| GT (1) | GT200600263A (enExample) |
| IL (1) | IL187486A0 (enExample) |
| MA (1) | MA29722B1 (enExample) |
| MX (1) | MX2007015430A (enExample) |
| NO (1) | NO20080244L (enExample) |
| TN (1) | TNSN07474A1 (enExample) |
| WO (1) | WO2006138317A2 (enExample) |
| ZA (1) | ZA200710769B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101647842B1 (ko) * | 2006-12-07 | 2016-08-11 | 다이이찌 산쿄 가부시키가이샤 | 저장 안정성이 개선된 의약 조성물 |
| EP2100610A4 (en) | 2006-12-07 | 2009-12-02 | Daiichi Sankyo Co Ltd | PHARMACEUTICAL COMPOSITION WITH LOW SUBSTITUTED HYDROXYPROPYL CELLULOSE |
| RU2470636C2 (ru) | 2007-04-27 | 2012-12-27 | Сайдекс Фамэсьютиклз, Инк. | Композиция клопидогреля и сульфоалкилового эфира циклодекстрина (варианты) и способы лечения заболеваний посредством названной композиции (варианты) |
| ES2769949T3 (es) | 2009-05-13 | 2020-06-29 | Cydex Pharmaceuticals Inc | Composiciones farmacéuticas que comprenden prasugrel y derivados de ciclodextrina y métodos de preparación y uso de las mismas |
| US10376532B2 (en) * | 2009-11-11 | 2019-08-13 | Chiesi Farmaceutici, S.P.A. | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
| TR201006802A1 (tr) * | 2010-08-17 | 2012-03-21 | Sanovel İlaç San. Ve Ti̇c. A.Ş. | Prasugrelin oral yolla dağılan formülasyonları. |
| EP2409685A3 (en) | 2010-07-19 | 2012-02-01 | Sanovel Ilac Sanayi ve Ticaret A.S. | Orally-disintegrating formulations of prasugrel |
| WO2016203018A1 (en) | 2015-06-19 | 2016-12-22 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Pharmaceutical compositions of prasugrel hydrobromide |
| WO2018167447A1 (en) * | 2017-03-14 | 2018-09-20 | University Of Sheffield | Low dose aspirin (1-50 mg) together with antiplatelets such as ticagrelor of anticoagulants |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI101150B (fi) * | 1991-09-09 | 1998-04-30 | Sankyo Co | Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi |
| US6509348B1 (en) * | 1998-11-03 | 2003-01-21 | Bristol-Myers Squibb Company | Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination |
| US6544981B2 (en) * | 2000-06-09 | 2003-04-08 | Bristol-Myers Squibb Company | Lactam inhibitors of factor Xa and method |
| JP4001199B2 (ja) * | 2000-07-06 | 2007-10-31 | 第一三共株式会社 | ヒドロピリジン誘導体酸付加塩 |
| KR20030014294A (ko) * | 2000-07-06 | 2003-02-15 | 상꾜 가부시키가이샤 | 히드로피리딘 유도체 산부가염 |
| PL206138B1 (pl) * | 2000-12-25 | 2010-07-30 | Daiichi Sankyo Company Limiteddaiichi Sankyo Company Limited | Kompozycja farmaceutyczna zawierająca aspirynę oraz zestaw i zastosowanie składników kompozycji |
| JP4874482B2 (ja) * | 2000-12-25 | 2012-02-15 | 第一三共株式会社 | アスピリンを含有する医薬組成物 |
| WO2004098713A2 (en) * | 2003-05-05 | 2004-11-18 | Eli Lilly And Company | Treating cardiovascular diseases with a compound of formula (i) (cs 747 - prasugrel; rn 150322-43-4) |
-
2006
- 2006-06-13 BR BRPI0612624A patent/BRPI0612624A2/pt not_active IP Right Cessation
- 2006-06-13 MX MX2007015430A patent/MX2007015430A/es unknown
- 2006-06-13 AU AU2006259538A patent/AU2006259538A1/en not_active Abandoned
- 2006-06-13 US US11/916,817 patent/US20090156632A1/en not_active Abandoned
- 2006-06-13 CN CNA2006800217943A patent/CN101198329A/zh active Pending
- 2006-06-13 JP JP2008517022A patent/JP2008543853A/ja active Pending
- 2006-06-13 CA CA002612315A patent/CA2612315A1/en not_active Abandoned
- 2006-06-13 WO PCT/US2006/023006 patent/WO2006138317A2/en not_active Ceased
- 2006-06-13 EP EP06773053A patent/EP1893205A4/en not_active Withdrawn
- 2006-06-13 KR KR1020077029366A patent/KR20080016647A/ko not_active Ceased
- 2006-06-13 EA EA200800075A patent/EA200800075A1/ru unknown
- 2006-06-16 GT GT200600263A patent/GT200600263A/es unknown
-
2007
- 2007-11-19 IL IL187486A patent/IL187486A0/en unknown
- 2007-12-11 ZA ZA200710769A patent/ZA200710769B/xx unknown
- 2007-12-14 TN TNP2007000474A patent/TNSN07474A1/en unknown
- 2007-12-14 EC EC2007008014A patent/ECSP078014A/es unknown
-
2008
- 2008-01-14 NO NO20080244A patent/NO20080244L/no not_active Application Discontinuation
- 2008-01-16 MA MA30577A patent/MA29722B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1893205A4 (en) | 2010-06-30 |
| MA29722B1 (fr) | 2008-09-01 |
| TNSN07474A1 (en) | 2009-03-17 |
| EA200800075A1 (ru) | 2008-04-28 |
| NO20080244L (no) | 2008-01-14 |
| CA2612315A1 (en) | 2006-12-28 |
| JP2008543853A (ja) | 2008-12-04 |
| ECSP078014A (es) | 2008-01-23 |
| AU2006259538A1 (en) | 2006-12-28 |
| MX2007015430A (es) | 2008-02-21 |
| KR20080016647A (ko) | 2008-02-21 |
| WO2006138317A3 (en) | 2007-05-03 |
| WO2006138317A2 (en) | 2006-12-28 |
| EP1893205A2 (en) | 2008-03-05 |
| US20090156632A1 (en) | 2009-06-18 |
| GT200600263A (es) | 2007-02-23 |
| IL187486A0 (en) | 2008-06-05 |
| BRPI0612624A2 (pt) | 2016-11-29 |
| CN101198329A (zh) | 2008-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL251539A0 (en) | Single pharmaceutical dosage form | |
| SI2343071T1 (sl) | Farmacevtske odmerne oblike | |
| IL182614A0 (en) | Pharmaceutical compounds | |
| ZA200710769B (en) | Dosage regimen for prasugrel | |
| IL181229A0 (en) | Noncardiotoxic pharmaceutical compounds | |
| GB0427455D0 (en) | Dosage forms | |
| GB0423964D0 (en) | Dosage form | |
| ZA200803152B (en) | Oramucosal pharmaceutical dosage form | |
| PL1912626T3 (pl) | Postaci użytkowe o polepszonej biodostępności | |
| GB0513984D0 (en) | Dosage form | |
| GB0616794D0 (en) | Solid dosage form | |
| GB0413818D0 (en) | Dosage unit | |
| GB0424742D0 (en) | Pharmaceutical compounds | |
| ZA200605666B (en) | Solid dosage form | |
| GB0428554D0 (en) | Pharmaceutical compounds | |
| HK1116083A (en) | Dosage regimen for prasugrel | |
| GB0522989D0 (en) | Dosage form | |
| GB0424994D0 (en) | Dosage form | |
| GB0411047D0 (en) | Dosage form | |
| GB0411669D0 (en) | Controlled-release dosage form | |
| GB0411667D0 (en) | Controlled-release dosage form | |
| GB0425810D0 (en) | Movable dosage indicator | |
| AU304365S (en) | Barrier bench | |
| GB0412894D0 (en) | Pharmaceutical compounds | |
| GB0415082D0 (en) | Pharmaceutical compounds |